Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Discovery Grants Program - Individual

McGill University

$42,050.00

Targeted radiopharmaceutical delivery to the brain

EF 2008-09

Résumé
Positron Emission Tomography (PET) and Single Photon Emission Tomography (SPECT) are imaging modalities to investigate diseases such as cancer and neurological disorders (Alzheimer's disease and Parkinson's disease). The biggest advantage for patients suffering from these diseases is that the actual investigation using these machines is completely non-invasive, involving no pain or discomfort. One drawback however is the use of radioactive substances serving as imaging agents to visualize the cancer or the receptor system involved in brain diseases. In the case of brain diseases only a small fraction of the injected imaging agent reaches the brain (<1%) and the rest of the radioactivity is found in other organs such as liver and kidney contributing to an unwanted radiation burden for the patient. The transport of the imaging agent into the brain is based on a very inefficient process called "passive diffusion" where no active transport is involved. We intend to develop a new generation of compounds for brain imaging based on the idea of coupling the imaging agent with a "molecular shuttle" responsible for active transport of this conjugate into the brain. A greater fraction of the imaging agent would enter the brain meaning that the overall dose of the compound could be decreased. This would ultimately reduce the radiation burden for the patient making these imaging methods better and also less expensive.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
355517-2008
Name nom
Schirrmacher, Ralf
Department département
Neurology and Neurosurgery
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2008
Award amount
42050
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
24
Committee name en
Inorganic & Organic Chemistry
Committee name fr
Chimie inorg. et org.
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
2402
Research subject group en
Nuclear engineering
Research subject group fr
Génie nucléaire
Research subject en
Radioactive materials
Research subject fr
Matériaux radioactifs
Partie
1
Nb partie
3
Application title
Targeted radiopharmaceutical delivery to the brain
Keyword
NA
Application summary
Positron Emission Tomography (PET) and Single Photon Emission Tomography (SPECT) are imaging modalities to investigate diseases such as cancer and neurological disorders (Alzheimer's disease and Parkinson's disease). The biggest advantage for patients suffering from these diseases is that the actual investigation using these machines is completely non-invasive, involving no pain or discomfort. One drawback however is the use of radioactive substances serving as imaging agents to visualize the cancer or the receptor system involved in brain diseases. In the case of brain diseases only a small fraction of the injected imaging agent reaches the brain (<1%) and the rest of the radioactivity is found in other organs such as liver and kidney contributing to an unwanted radiation burden for the patient. The transport of the imaging agent into the brain is based on a very inefficient process called "passive diffusion" where no active transport is involved. We intend to develop a new generation of compounds for brain imaging based on the idea of coupling the imaging agent with a "molecular shuttle" responsible for active transport of this conjugate into the brain. A greater fraction of the imaging agent would enter the brain meaning that the overall dose of the compound could be decreased. This would ultimately reduce the radiation burden for the patient making these imaging methods better and also less expensive.